TY - JOUR
T1 - Th1Th17CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment
AU - Quirant-Sánchez, Bibiana
AU - Presas-Rodriguez, Silvia
AU - Mansilla, María José
AU - Teniente-Serra, Aina
AU - Hervás-García, José V.
AU - Brieva, Luis
AU - Moral-Torres, Ester
AU - Cano, Antonio
AU - Munteis, Elvira
AU - Navarro-Barriuso, Juan
AU - Martínez-Cáceres, Eva M.
AU - Ramo-Tello, Cristina
PY - 2019/1/1
Y1 - 2019/1/1
N2 - © 2019 Bibiana Quirant-Sánchez et al. Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n = 22) or fingolimod (n = 44) treatment, by flow cytometry. A correlation study between the percentage and absolute cell number of each lymphocyte subpopulation with the presence of relapses or new MRI lesions during 12-month follow-up was performed. Patients who had undergone relapses showed at baseline higher percentage of Th1CM cells (relapsed: 11 60 ± 4 17%vs. nonrelapsed: 9 25 ± 3 17%, p < 0 05) and Th1Th17CM cells (relapsed: 15 65 ± 6 15%vs. nonrelapsed: 10 14 ± 4 05%, p < 0 01) before initiating DMF or fingolimod treatment. Kaplan-Meier analysis revealed that patients with Th1Th17CM (CD4+CCR7+CD45RA-CCR6+CXCR3+) cells > 11 48% had a 50% relapse-free survival compared to patients with Th1Th17CM cells < 11 48% whose relapse-free survival was 88% (p = 0 013, log-rank test). Additionally, a high percentage of Th1Th17CM cells was also found in patients with MRI activity (MRI activity: 14 02 ± 5 87%vs. no MRI activity: 9 82 ± 4 06%, p < 0 01). Our results suggest that the percentage of Th1Th17CM lymphocytes at baseline is a predictive biomarker of activity during the first 12 months of treatment, regardless of the treatment.
AB - © 2019 Bibiana Quirant-Sánchez et al. Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n = 22) or fingolimod (n = 44) treatment, by flow cytometry. A correlation study between the percentage and absolute cell number of each lymphocyte subpopulation with the presence of relapses or new MRI lesions during 12-month follow-up was performed. Patients who had undergone relapses showed at baseline higher percentage of Th1CM cells (relapsed: 11 60 ± 4 17%vs. nonrelapsed: 9 25 ± 3 17%, p < 0 05) and Th1Th17CM cells (relapsed: 15 65 ± 6 15%vs. nonrelapsed: 10 14 ± 4 05%, p < 0 01) before initiating DMF or fingolimod treatment. Kaplan-Meier analysis revealed that patients with Th1Th17CM (CD4+CCR7+CD45RA-CCR6+CXCR3+) cells > 11 48% had a 50% relapse-free survival compared to patients with Th1Th17CM cells < 11 48% whose relapse-free survival was 88% (p = 0 013, log-rank test). Additionally, a high percentage of Th1Th17CM cells was also found in patients with MRI activity (MRI activity: 14 02 ± 5 87%vs. no MRI activity: 9 82 ± 4 06%, p < 0 01). Our results suggest that the percentage of Th1Th17CM lymphocytes at baseline is a predictive biomarker of activity during the first 12 months of treatment, regardless of the treatment.
UR - http://www.mendeley.com/research/th1th17cm-lymphocyte-subpopulation-predictive-biomarker-disease-activity-multiple-sclerosis-patients
U2 - 10.1155/2019/8147803
DO - 10.1155/2019/8147803
M3 - Article
C2 - 31346315
SN - 0962-9351
VL - 2019
JO - Mediators of Inflammation
JF - Mediators of Inflammation
M1 - 8147803
ER -